ANIK Q2 2024 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$213M

Q2 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$31M-30.6% YoY

Gross Profit

$20M66.7% margin

Operating Income

-$2M-5.9% margin

Net Income

-$88,000-0.3% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

-24.2%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$4M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$263M

Total Liabilities

$52M

Stockholders' Equity

$210M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$44M	-30.6%
Gross Profit	$20M	$29M	-29.3%
Operating Income	-$2M	-$4M	+50.2%
Net Income	-$88,000	-$3M	+96.8%

Revenue Segments

Joint Preservation and Restoration

$14M89%

Non-Orthopedic

$2M11%

Geographic Segments

UNITED STATES

$29M81%

Europe

$7M19%